Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
Article
[키워드] 95% CI
appear
B.1.1.529
B.1.617.2
BNT
BNT162b2
BNT162b2 mRNA
booster
booster dose
chronic liver disease
cirrhosis
compensated
Control
control group
COVD-19
COVID-19
COVID-19 in patient
COVID-19 vaccines
COVID-19-related death
Critical
dose
doses
General population
greater
hepatic decompensation
hyporesponsiveness
immune dysregulation
liver
magnitude
moderate
Moderate COVID-19
Moderna mRNA-1273 vaccine
mRNA vaccine
mRNA-1273
mRNA-1273.
outcome
overcome
participant
Patient
Pfizer
predominant
receipt
reduction in
retrospective cohort study
risk of infection
Support
symptomatic
the vaccine
Vaccine
Vaccines
variants
veteran
with COVID-19
[DOI] 10.1016/j.jhep.2022.07.036 PMC 바로가기
[DOI] 10.1016/j.jhep.2022.07.036 PMC 바로가기